Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02934256
Other study ID # Tian-drug-neuro002
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date July 2016
Est. completion date July 2018

Study information

Verified date September 2021
Source Beijing Tiantan Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

1)Preliminarily evaluate the treatment effect of Icotinib Hydrochloride Tablets on NF2; 2)Preliminarily evaluate the safety and the patient's tolerance of the treatment of Icotinib; 3)Provide an objective basis for an enlarged randomized double-blind trial.


Description:

Read more »
Read more »

Study Design


Intervention

Drug:
Icotinib
Method of drug administration:oral; Dosage: 125mg/m3/d; Course of treatment: 3 months;Total four treatment courses.

Locations

Country Name City State
China Beijing Tiantan Hospital Affiliated to Capital Medical University Beijing Beijing
China Beijing Tiantan Hospital Affiliated to Capital Medical University Beijing

Sponsors (2)

Lead Sponsor Collaborator
Li Peng Betta Pharmaceuticals Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Change from baseline in QOL(quality of life) score after every course of the treatment Patients' QOL(quality of life) would be evaluated after every course of the treatment. Baseline,Month 3,Month 6,Month 9,Month 12
Primary Change from Baseline in volume of tumour after every course of the treatment Patients in this clinical trial would receive MRI test to evaluate the volume of tumour after every course of the treatment. Baseline,Month 3,Month 6,Month 9,Month 12
Secondary Change from Baseline in hearing ability after every course of the treatment Patients' hearing ability would be tested after every course of the treatment. Baseline,Month 3,Month 6,Month 9,Month 12
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Active, not recruiting NCT00973739 - Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Phase 2
Completed NCT04351373 - Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560 Phase 2
Active, not recruiting NCT01449604 - Stereotactic Radiation in Vestibular Schwannoma Phase 3
Completed NCT01207687 - Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Phase 2
Not yet recruiting NCT05567341 - Remote Ischemic Preconditioning in Vestibular Schwannoma Surgery N/A
Completed NCT02249572 - Vestibular Schwannoma - Radiosurgery or Expectation: V-REX. N/A
Terminated NCT05116878 - Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma N/A
Suspended NCT03095248 - Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Phase 2
Recruiting NCT04801953 - Nimodipine in Vestibular Schwanommas Phase 2
Recruiting NCT03745560 - Intraoperative EABR for Decision Making
Recruiting NCT04859335 - Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma N/A
Recruiting NCT04128345 - Novel Multimodality Imaging for Navigation in Skull Base Surgery
Active, not recruiting NCT01199978 - Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Phase 2
Recruiting NCT04057976 - Use of DTT to Define Facial Nerve Position in Vestibular Schwannomas N/A
Completed NCT00863122 - Concentration and Activity of Lapatinib in Vestibular Schwannomas Early Phase 1
Recruiting NCT04374305 - Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) Phase 2
Recruiting NCT03079999 - Study of Aspirin in Patients With Vestibular Schwannoma Phase 2
Recruiting NCT05786144 - Vestibular Schwannoma Organoids
Recruiting NCT03593577 - Secondary Endolymphatic Hydrops and Vestibular Schwannomas on 3 Tesla MRI